Closed-loop drug delivery promises autonomous control of pharmacotherapy through the
continuous monitoring of biomarker levels. For decades, researchers have strived for …

The selection of an appropriate therapy and dosing regimen is a significant challenge in the
treatment of cancer. Although there are recommended standardized chemotherapy …

Cancer treatment is becoming more and more individually based as a result of the large
inter-individual differences that exist in treatment outcome and toxicity when patients are …

Simple Summary Accelerated clinical development of anticancer drugs is crucial to ensure
patients' access to the most safe and effective treatments. At the same time, the development …

Certain oncology compounds exhibit fundamental pharmacokinetic (PK) disparities between
healthy and malignant conditions. Given the effects of tumor‐associated inflammation on …

Background Bevacizumab treatment is subject to large interpatient variability in efficacy,
which may partly be explained by differences in complex bevacizumab pharmacokinetic …

Bevacizumab is a monoclonal antibody that targets VEGF-A and inhibits tumor
angiogenesis. Bevacizumab is approved for the treatment of various cancer, including …

An outstanding challenge in the clinical care of cancer is moving from a one-size-fits-all
approach that relies on population-level statistics towards personalized therapeutic design …

6-Mercaptopurine (6-MP) is used extensively in the treatment of acute lymphoblastic
leukemia (ALL) and inflammatory bowel diseases. Our laboratory determined previously …

Imatinib is a targeted cancer therapy that has significantly improved the care of patients with
chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). However, it has …